Nanobac Pharmaceuticals, Inc. announces New Leadership Team.Business Editors/Health/Medical Writers
TAMPA, Fla.--(BUSINESS WIRE)--Jan. 29, 2004
Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP) ("Nanobac" or "The Company").
John Stanton, Chairman of the Board, announced effective 01/29/04 the following organization changes: Mr. Stanton said this was in keeping with an earlier announcement to bring on board a strong team of NanoTechnology Scientists and Researchers, as well as experienced professionals in the BioLife Sciences business.
Alexander H. Edwards, III will become President/Chief Executive Officer and Board member of Nanobac Pharmaceuticals, Inc. Prior to joining Nanobac, Edwards was a managing partner of 360 Partners as well as president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of 360 Energy. Before that, he was in private consulting practice utilizing his experiences with leadership in healthcare growth companies.
From January 1997 to May 2002, Edwards was an executive with SRI/Surgical Express. He served in roles that ranged from vice-president/general manager to spending his last year with the company as president. Previous to this, he worked in sales and marketing with Dianon Systems, Inc. His positions included sales and sales management roles as well as field and corporate marketing. Edwards also served as an officer in the United States Navy United States Navy
Major branch of the U.S. military forces, charged with defending the nation at sea and maintaining security on the seas wherever U.S. interests extend. The Continental Navy was established by the Continental Congress in 1775. with duty assignments ranging from shipboard divisional leadership to executive assistant for the Naval Surface Group Commander in Norfolk, Virginia.
Edwards is a 1987 graduate of the United States Naval Academy United States Naval Academy, at Annapolis, Md.; for training young men and women to be officers of the U.S. navy or marine corps. George Bancroft, Secretary of the Navy, founded and opened (1845) it as the Naval School at Annapolis. .
Brady Millican will replace Mr. Edwards as Vice President/Chief Operating Officer for the company. Mr. Millican has over 12 years of leadership experience and a comprehensive background in diagnostics infrastructure including clinical trial and research development support. Prior to joining Nanobac, Brady was Director of Business Development and Strategic projects at AmeriPath, a leading national provider of cancer diagnostics, genomics, and related information services See Information Systems. .
Previous to this he worked at Pathology Service Associates in various leadership roles ranging from directing marketing activities to developing revenue enhancement revenue enhancement
An increase in revenues, especially by way of increased taxes. Revenue enhancement includes reducing taxpayer deductions and eliminating tax credits. audits. Millican also worked at Dianon Systems, Inc. in Sales and sales management roles, as well as field and corporate marketing.
Millican served as an officer in the United States Army United States Army
Major branch of the U.S. military forces, charged with preserving peace and security and defending the nation. The first regular U.S. fighting force, the Continental Army, was organized by the Continental Congress on June 14, 1775, to supplement local as a helicopter pilot, and is airborne and ranger qualified. Millican received his Bachelor of Arts Degree in Psychology (emphasis in Industrial Psychology - motivation) from Washington and Lee University Washington and Lee University, at Lexington, Va.; coeducational; founded and opened 1749 as Augusta Academy. It was called Liberty Hall in 1776; became Liberty Hall Academy (a college) in 1782, Washington Academy (following a gift from George Washington) in 1798, in 1983.
Michael Dean will continue as Controller. He has a B.A. in Accounting and obtained his B.A. in Accounting Information systems from the University of West Florida
He started his career at Shell Oil Company, then became a Staff Accountant at Harper VanScoik & Company, a regional CPA firm. Then to CGI CGI
in full Common Gateway Interface.
Specification by which a Web server passes data between itself and an application program. Typically, a Web user will make a request of the Web server, which in turn passes the request to a CGI application program. (IMR IMR - Internet Monthly Report Global Corp) where he served as Controller, then V.P. of Finance and Chief Financial Officer. Dean brings 19 years of knowledge in Finance, Taxes, SEC filing and International experience.
For additional information refer to Bios on our website, http://www.nanobaclabs.com, under the heading, "The Company".
Mr. Stanton also announced the complete restructuring of the Research and Science Institution.
With the completion of the acquisition of Nanobac OY in Kuopio, Finland, it is now possible to combine all the company's intellectual knowledge in to one group.
The new group will be Nanobac Science and Research Institute, a division of Nanobac Pharmaceuticals, Inc., with offices in Kuopio, Finland and Tampa, Florida. This group is recognized as the world leaders in the Science and Research of Nanobacteria sanguineum, its effects and causes, and the diseases that are implicated im·pli·cate
tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates
1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot.
Dr. Olavi Kajander, MD, PhD will be the Managing Director of Nanobac OY and Chief Science & Research Officer for the company. Dr. Kajander is the founder of Nanobac OY, a Finnish research and development company located in Kuopio, Finland, where, along with Dr. Neva Ciftcioglu, he documented and patented their discovery of Nanobacteria. Nanobac OY is now a Finnish research subsidiary of Nanobac Pharmaceuticals, Inc. He was also the founder of Abcell Corporation, a medical diagnostics company.
In addition to being the Chief of Science and Research Officer at Nanobac, Dr. Kajander is also a docent (full professor) and director of research of the department of biochemistry at the University of Kuopio The University of Kuopio (Finnish Kuopion yliopisto) is situated in the town of Kuopio in Eastern Finland. The University's Foundation Act was passed in 1966, and teaching started in 1972. (Kuopio, Finland). His position at the University of Kuopio has elevated over the time of his tenure from Ph.D. candidate, to doctorate, assistant professor, associate professor and now as docent. He has taught many courses at the university for more than 12 years.
Dr. Kajander was a Scripps Clinic & Resident Foundation post-doctoral research fellow in La Jolla, California. He has authored more than 70 scientific research papers and review articles, two letters and more than 50 scientific abstract publications as well as several invited editorials in scientific texts and journals. He has also been involved in the production of a number of videos and documentaries about his discovery of Nanobacteria. He has two families of U.S. patents that are effective in many countries and another family of U.S. patents that are pending issue.
In 1999, together with fellow researcher Dr. Neva Ciftcioglu, Dr. Kajander won the Minerva, Medix award for the most prominent Finnish biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. paper of 1998. He has also won the Martti Hamalainen Young Researcher Award, the Swedish Medical Association, Riksmassan, Honorary Bronze Medal and the Korczynski Award and Honorarium HONORARIUM. A recompense for services rendered. It is usually applied only to the recompense given to persons whose business is connected with science; as the fee paid to counsel.
2. for the advancement of biopharmaceutical sciences.
Dr. Kajander is a member of the Biochemical Society, the New York Academy of Sciences The New York Academy of Sciences is the third oldest scientific society in the United States. An independent, non-profit organization with more than 25,000 members in 140 countries, the Academy’s mission is to advance understanding of science and technology. , FEMS, the Finnish Immunology Society, the Finnish Physiology Society and Duodecim. He has also served on numerous scientific advisory boards.
Dr. Neva Ciftcioglu, PhD will serve as Scientific Advisor to the company. Born in Turkey, Neva Ciftcioglu, Ph.D. is a co-discoverer and a principal researcher of Nanobacterium Nanobacteria are said to be cell-walled microorganisms with a diameter well below the generally accepted lower limit (about 200 nanometres) for bacteria. 200 nm happens to be the size of the smallest object which could be resolved in a standard light microscope. sanguineum with Dr. E. Olavi Kajander. Dr. Ciftcioglu has been a scientific collaborator with NanobacLabs Research Institute since 1999. Drs. Ciftcioglu and Kajander are regarded as the world's experts in Nanobacterial research. While her early work centered on general infectious diseases and bacterial pathogencity, her recent area of interest is in cell culture techniques, immunoassays and monoclonal antibodies and nanobacterial pathogenicity.
She is a Docent (full professor) of biochemistry at the University of Kuopio in Kuopio, Finland and a senior scientist and director of nanobacterial research for the Universities Space Research Association, NASA NASA: see National Aeronautics and Space Administration.
in full National Aeronautics and Space Administration
Independent U.S. Johnson Space Center, Houston, Texas. She also collaborates or directs with Dr. Kajander, nanobacterial research projects at more than 100 sites.
Dr. Ciftcioglu holds an undergraduate degree from Kocatepe Mimar Kemal Lisesi, in Ankara, Turkey and both a master's degree and a doctorate degree in microbiology from the University of Ankara. She served as a post-doctoral research fellow in Dr. Kajander's research group at the University of Kuopio.
Dr. Ciftcioglu's work has been recognized through a number of scientific awards including the 1993, 1996 and 1998 Savon Korkean Teknologian Saatio Award (Finland) and the 1997 and 1998 Jenny ja Antti Wihurin Rahasto Award (Finland). She was also awarded the 1999 Minerva, Medix Prize for the most prominent Finnish biomedical paper of 1998. Dr. Ciftcioglu has authored or co-authored 46 scientific publications and 17 scientific abstract communications.
She is a professional member of NABI NABI North American Bus Industries
NABI Native American Basketball Invitational
NABI National Amateur Bowlers Incorporated
NABI National Association of Background Investigators (NASA Astrobiology Institute The NASA Astrobiology Institute (NAI) engages in government-funded Exobiologic study of the living universe. Advances in science and technology are yielding dramatic new knowledge about the origin, distribution, and destiny of life. ), the American Society for Microbiology The American Society for Microbiology (ASM) is a scientific organization, based in the United States although with over 43,000 members throughout the world. It is the largest single life science professional organization and its members include those whose interests encompass basic , the American Society for Cell Biology, the Societas biochemical et microbiological Fenniae and the Societas Physiologica Finlandiae. She lectures to professional societies and universities worldwide on the subject of nanobacteria.
Dr. Ciftcioglu is on assignment at NASA in Houston, TX at this time. These two scientists are recognized as the world leaders in the field of Nanobacteria science and research.
"We are extremely excited with our reorganized team," commented Stanton. "We have begun the process of seating outside Directors and are working to finalize our Advisory Board."
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at http://www.nanobaclabs.com or contact us at firstname.lastname@example.org.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates Growth Rates
The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures.
Remember, historically high growth rates don't always mean a high rate of growth looking into the future. ), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which might cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report, these statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.